Home > Technology Platforms > π-Icosa™ AAV Serotype Screening Platform

π-Icosa™ AAV Serotype Screening Platform

AAV product banner

With its proprietary π-Icosa™ High-capacity and High-precision AAV serotype screening platform PackGene aims to identify maximally infective and tissue-specific AAV serotypes for clinical trial development. High infectivity and tissue specificity can ultimately reduce the dosage and production cost of AAV-based gene therapies while simultaneously increasing safety and efficacy.

Advantages of π-Icosa™ High-capacity and High-precision AAV serotype screening:

  • Capacity: Our platform design results in higher library capacity
  • Precision: Higher precision AAV-serotype screening
  • Efficacy: High infectivity and tissue specificity can result in reduced dosage requirements that increaseboth safety and efficacy.
Interested in our AAV services? Please contact us for a free consultation or  submit a request for a quotation.

Intellectual property:

PackGene has three patents pending.

tissue targeting aav
  • Library>1 billion mutants
  • Screens AAVs for tissue specificity.

With its proprietary π-Icosa™ High-capacity and High-precision AAV serotype screening platform PackGene aims to identify maximally infective and tissue-specific AAV serotypes for clinical trial development. High infectivity and tissue specificity can ultimately reduce the dosage and production cost of AAV-based gene therapies while simultaneously increasing safety and efficacy.